Viatris Inc. has announced positive top-line results from the VEGA-3 trial, the second pivotal Phase 3 study evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for treating presbyopia. The trial met its primary and all secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity without compromising distance vision. The safety profile was consistent with previous clinical trials, with no treatment-related serious adverse events reported. The study involved 545 patients and showed significant improvements in visual acuity compared to placebo. Viatris plans to submit an application to the U.S. FDA in the second half of 2025. Results from this study have already been presented.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。